<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499239</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-193-0101</org_study_id>
    <nct_id>NCT00499239</nct_id>
  </id_info>
  <brief_title>A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)</brief_title>
  <official_title>Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult
      patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study
      in sequential dose cohorts.

      Patients will be administered a single IV infusion of GS 9219 on Day 1 of a 21 day cycle and
      may receive a total of six treatment cycles based on toxicities and response. Patients who
      demonstrate disease progression will be discontinued from the study. Patients who, at the
      completion of six treatment cycles, tolerate treatment and show evidence of disease control
      (response or stabilization) will be eligible to continue receiving treatment at the same
      dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is as follows:

      To assess the safety, toxicity, and maximum tolerated dose (MTD) of GS 9219 administered via
      IV administration once every three weeks (21 days) for six treatment cycles, i.e. for a total
      of 18 weeks, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL),
      Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM).

      The secondary objectives of this study are as follows:

      To determine the pharmacokinetic parameters of GS 9219 for this regimen and patient
      population.

      To assess the antitumor activity of GS 9219 based on Response Rate and Duration of Response.
      Progression-free Survival and Overall Survival will be assessed if applicable.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unacceptable safety profile
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD</measure>
    <time_frame>All visits</time_frame>
    <description>Toxicity will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE). The MTD will be the highest dose level immediately below the dose level where two or more of three to six patients experience a dose-limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GS-9219 and its metabolites</measure>
    <time_frame>AAA) CLL/NHL: at Cycles 1, 3, and 6: MM: Cycles 1, 2, 3, 4, 5, and 6</time_frame>
    <description>Pharmacokinetics (Cmax, Tmax, Clast, Tlast, Î»z, t1/2, AUClast, AUCinf, and %AUCexp) measured by blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>CLL/NHL: at Cycles 1, 3, and 6: MM: Cycles 1, 2, 3, 4, 5, and 6</time_frame>
    <description>Response rate measured by:
CLL: National Cancer Institute Working Group (NCIWG) criteria
NHL - National Cancer Institute (NCI) criteria; Response Evaluation in
MM - International Myeloma Working Group (IMWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>CLL/NHL: at Cycles 1, 3, and 6: MM: Cycles 1, 2, 3, 4, 5, and 6</time_frame>
    <description>Duration of response measured by:
CLL: National Cancer Institute Working Group (NCIWG) criteria
NHL - National Cancer Institute (NCI) criteria; Response Evaluation in
MM - International Myeloma Working Group (IMWG) criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>GS-9219</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9219</intervention_name>
    <description>GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.
GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days.</description>
    <arm_group_label>GS-9219</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory CLL, NHL or MM

          -  ECOG Performance Status of 0, 1, or 2

          -  Adequate organ function (protocol defined)

          -  ECG without evidence of clinically significant ventricular arrhythmias

        Exclusion Criteria:

          -  AIDS-related lymphoma

          -  Subjects with NHL who present exclusively with non-measurable lesions

          -  Subjects with MM who have non-secretory and/or non-measurable disease

          -  Recent anticancer therapy (chemotherapy, radiotherapy, and/or biotherapy)within four
             weeks prior to starting treatment

          -  Evidence of pulmonary fibrosis

          -  Other concurrent malignancy

          -  Uncontrolled concurrent illness

          -  Receiving chronic, systemically administered steroids

          -  Known hypersensitivity to nucleoside analogues
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno - Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>10 100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice</name>
      <address>
        <city>Praha</city>
        <zip>2 128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution: Medical Radiological Research Center under the Russian Academy of Medical Sciences</name>
      <address>
        <city>Kaluga Region</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State institution Main Military Clinical Hospital n.a.academician N.N. Burdenko under the Ministry of Defense of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Hematological Research Center under the Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Institution: Municipal Clinical Hospital n.a. S.P. Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Medical Institution Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Public Medical Institution of Novosibirsk Region: State Novosibirsk Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution: Research Institute of Hematology and Blood Transfusion under Federal Agency for High-Tech Medical Care</name>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution St. Petersburg State Medical University n.a. I.P. Pavlov under the Federal Agency for Healthcare and Social Development, Institute of Hematology and Transplantology n.a. R.M. Gorbacheva</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution St. Petersburg State Medical University n.a. I.P. Pavlov under the Federal Agency for Healthcare and Social Development</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution Russian Research Center of Radiology and Surgical Technologies under the Federal Agency for High-Tech Medical Care</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <disposition_first_submitted>January 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2014</disposition_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>CLL</keyword>
  <keyword>NHL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>CLL and NHL</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>MM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

